Table 3.

Multivariable Cox regression of preplanned OS analysis

Covariate	HR (95% CI)	P
Treatment arm (venetoclax vs placebo)	0.67 (0.47-0.96)	.03
Age (<75 vs ≥75 y)	0.56 (0.37-0.84)	.005
AML status (de novo vs secondary)	0.59 (0.41-0.85)	.004
ECOG performance status (<2 vs ≥2)	0.48 (0.33-0.70)	<.001
Cytogenetic risk (intermediate vs poor)	0.57 (0.40-0.82)	.003